Accumulation of Dietary Docosahexaenoic Acid in the Brain Attenuates Acute Immune Response and Development of Postischemic Neuronal Damage

Mélanie Lalancette-Hebert, PhD; Carl Julien, PhD; Pierre Cordeau, MSc; Ivan Bohacek, MD; Yuan-Cheng Weng, MSc; Frédéric Calon, PhD; Jasna Kriz, MD, PhD

Background and Purpose—Consumption of fish has been shown to reduce risk of coronary heart disease and, possibly, of ischemic stroke. Because docosahexaenoic acid (DHA) is the most likely neuroactive component within fish oil, we hypothesized that exposing mice to a DHA-enriched diet may reduce inflammation and protect neurons against ischemic injury.

Methods—To visualize the effects of DHA on neuroinflammation after stroke, TLR2-fluc-GFP transgenic mice were exposed to either a control diet, a diet depleted in n-3 polyunsaturated fatty acid, or a diet enriched in DHA during 3 months. Real-time biophotonic/bioluminescence imaging of the TLR2 response was performed before and after middle cerebral artery occlusion, whereas cytokines concentrations and stroke area analyses were performed at 3 and 7 days after middle cerebral artery occlusion, respectively.

Results—We show that a 3-month DHA treatment prevented microglial activation after ischemic injury, reduced the ischemic lesion size, and increased levels of the antiapoptotic molecule Bcl-2 in the brain. Additional analysis revealed a significant decrease in the levels of COX2 and IL-1β, but not in other proinflammatory cytokines. Importantly, long-term DHA supplementation significantly changed the n-3:n-6 polyunsaturated fatty acid ratio in the brain.

Conclusions—Collectively, these data indicate that diet-induced accumulation of DHA in the brain protects against postischemic inflammation and injury. Because DHA is widely available at low cost and has an excellent safety profile, our data suggest that increased DHA intake may provide protection against acute immune response/brain damage in ischemic stroke. (Stroke. 2011;42:2903-2909.)

Key Words: stroke ■ nutraceutical ■ biophotonic/bioluminescence imaging ■ neuroinflammation ■ TLR2-reporter mouse

Cardiovascular diseases, which include coronary heart disease and stroke, are leading causes of death and disability in industrialized countries and, therefore, identifying primary prevention strategy represents a public health priority.1 Large prospective cohort studies and randomized trials have shown that fish oil intake decreases the risk of death from coronary heart disease. Several lines of epidemiological evidence also indicate that consumption of fish is associated with reduced risk of ischemic stroke,2 although this association is not consistently detected.3 Because fish is a major source of docosahexaenoic acid (DHA, 22:6n-3), it can be hypothesized that DHA is a potential nutraceutical candidate for treatment of ischemic stroke.

Accumulation of DHA in the brain has been associated with reduction of neuroinflammation4–7 and activation of antiapoptotic pathways,8 2 mechanisms of action implicated in ischemic stroke. Given that restraining acute inflammatory processes may be beneficial in ischemic stroke,1,9 we hypothesized that long-term intake of DHA-enriched diet may change n-3:n-6 PUFA ratio in cerebral tissue, thereby protecting brain cells from an uncontrolled inflammation response and consequent ischemic injury.

By using mouse models for live biophotonic/bioluminescence imaging of microglial activation, we report here that diet-induced accumulation of DHA in the brain modulates postischemic inflammation/innate immune response and protects against ischemic injury.

Materials and Methods

Experimental Animals

All experiments were performed on TLR2-fluc-GFP transgenic mice (C57BL/6 background), in which luciferase and GFP reporters are
driven under the transcriptional control of the murine Toll-like receptor 2 gene promoter. Males (n=9–12 per group, age 2–3 months) were put on 1 of the customized diets (Supplemental Table 1, http://stroke.ahajournals.org) for 3 months (Figure 1). The formulas of these isocaloric purified diets were precisely determined to avoid batch-to-batch disparity (Supplemental Table 1). DHA-treated mice received approximately 0.7 g/kg per day of DHA, protected from oxidation through gelatin microencapsulation (MEG-3, Ocean Nutrition Inc). All experimental procedures were approved by the Laval University Animal Care Ethics Committee and are in accordance with the Canadian Council on Animal Care.

Surgical Procedures
As described,10–13 the surgery was performed on 2- to 3-month old male mice (transgenics in C57BL/6 background; 20–25 g). The animals were anesthetized (2% isoflurane) and unilateral transient focal cerebral ischemia was induced by intraluminal filament occlusion (12 mm long 6–0 silicon-coated monofilament) of the left middle cerebral artery (MCAO) during 1 hour followed by 24- to 72 hours or 7 days reperfusion. To avoid cooling for the first night at room temperature using primary antibodies: 1:750 Rabbit polyclonal anti-Iba1 (Wako), 1:50 mouse monoclonal anti-green fluorescent protein (GFP; Invitrogen). After wash, the sections were incubated in corresponding fluorescent goat secondary antiserum (Invitrogen).

Immunofluorescence Analysis
As previously described,13,14 the images were gathered using IVIS® 200 Imaging System (CaliperLS-Xenogen). Twenty-five minutes before imaging session, the mice received intraperitoneal injection of D-luciferine (150 mg/kg; CaliperLS-Xenogen). The samples were postfixed overnight in 4% paraformaldehyde in 1X Cell Lysis Buffer (included in the Ray Biotech kit) with Protease inhibitor cocktail (Sigma #P8340). The proteins were separated on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes, and detected using monoclonal primary antibodies against anti-COX2 (1:2,000; Sigma), and anti-Bcl-2, and rabbit polyclonal antibody (1:750; New England Biolabs) and antibax (1:750; New England Biolabs). The Western blots were revealed using the western lightning chemiluminescence kit (Perkin Elmer).

Lipid Extraction and Gas Chromatography
The determination of fatty acid content was performed in frozen extracts from the contralateral striatum, using previously published procedures.14

Statistical Analysis
All data are expressed as mean±SEM. Statistical difference was assessed by 1-way analysis of variance (ANOVA) followed by post hoc comparison (Bonferroni’s) test (P≤0.05). When appropriate, nonparametric analysis was conducted using a Kruskal-Wallis test.

Results
DHA-Enriched Diet Attenuates Acute Microglial Activation/TLR2 Response and Decreases Ischemic Lesion
We investigated whether long-term intake of DHA may change n-3:n-6 PUFA ratio in the brain and modulate postischemic inflammation. As shown in Figure 1, TLR2 reporter mice were put on either control, n-3-PUFA-depleted, or DHA-enriched diets (Supplemental Table 1) for a period of 3 months and then were subjected to transient MCAO (Figure 1). After stroke, the microglial activation/innate immune responses were longitudinally imaged from the brains of live TLR2-luc-GFP mice (Figure 2A). As shown in Figure 2C, D and as demonstrated in our previous study, after stroke the TLR2-driven GFP transgene was strongly induced in microglial cells.10 The quantitative analysis of photon emissions revealed a strong anti-inflammatory effect of DHA treatment at 6, 24, and 48 hours after cerebral ischemia as compared with control or low n-3 PUFA diet (Figure 2B). Overall, chronic DHA treatment almost completely blunted induction of TLR2 promoter, suggesting profound preventive effects of DHA against postischemic inflammation. Next, we investi-
gated whether DHA treatment affected early monocyte recruitment after stroke. To analyze whether the robust anti-inflammatory effect of DHA-enriched diet was associated with neuroprotection, we measured stroke area at 48 hours and at 7 days after MCAO. As shown in Figure 3A,B, the analysis of cresyl-violet-stained brain sections at 48 hours and at 7 days after MCAO revealed a significant decrease in the size of ischemic lesions in mice subjected to DHA-enriched diet compared with control and low n-3 PUFA diets (*\(P < 0.05\)).

Previous work suggests that DHA may inhibit neuronal apoptosis through activation of cell survival pathways. Therefore, we analyzed the levels of anti- and proapoptotic proteins in ischemic brains of mice subjected to DHA-enriched diets. Western blot analysis revealed that DHA-enriched diet increased levels of the antiapoptotic protein Bcl-2 after stroke, (Figure 4A) although left levels of proapoptotic protein Bax unchanged (Figure 4B). Hence, the DHA-mediated decrease in size of ischemic lesion was associated with increased levels of Bcl-2.

**Long-Term Dietary DHA Intake Changes the Content of a Total Brain Fatty Acid Levels and Decreases Proinflammatory Cytokines After Stroke**

Next, we investigated whether observed anti-inflammatory/neuroprotective effects were indeed caused by change in n-3:n-6 PUFA ratio in the brain. As shown in Figure 5, the DHA-supplemented diet significantly increased concentrations of DHA in the striatum, a value 10% higher than in controls (\(P < 0.05\)) and 28% higher than in animals fed low n-3 PUFA diet (\(P < 0.001\); Figure 5A). Moreover, DHA treatment decreased the levels of arachidonic acid (ARA), an n-6 PUFA with inflammatory properties, in the striatum.
(-11% and -17% versus control and low n-3 PUFA diets, respectively; Figure 5B). Furthermore, we found a significant upward shift in overall n-3:n-6 PUFA ratio in the brains of mice on DHA-supplemented diet (ratio 1.13) as compared with control (ratio 0.92) and the low n-3/high n-6 PUFA diet (ratio 0.67; Figure 5C). Overall, long-term, high-DHA intake led to a significant increase in concentration of the brain anti-inflammatory n-3 PUFA and a decrease in levels of the proinflammatory of n-6 PUFA.

Differential Effects of n-3 and n-6 PUFA on Proinflammatory Cytokines Levels

There is growing evidence that postischemic inflammation plays an important role in the evolution of ischemic brain injury. One of the characteristics of the brain inflammatory response 24 to 72 hours after transient MCAO is a marked increase in the levels of proinflammatory cytokines such as IL-1β, TNF-α, and IL-6. Here, we found that chronic n-3 PUFA depletion potentiated the postischemic increase in IL-1β and IL-6 compared with controls (Figure 6A and C). In contrast, supplementation with high-DHA selectively prevented the increase of IL-1β in ischemic brains compared with animals fed n-3-PUFA-depleted and/or control diets (Figure 6A). Interestingly, we did not observe any PUFA-induced effects on the expression levels of TNF-α (Figure 6B).

Competition between n-6 and n-3 PUFA occurs at the level of prostaglandin formation at the cyclooxygenase (COX) and lipoxygenase levels. Previous studies suggest that n-3 PUFAs such as DHA can suppress induction of COX-2 by competing with ARA for enzymatic metabolism, inducing the production of less inflammatory derivatives. Therefore, we hypothesized that shifting upward the n-3:n-6 PUFA ratio in the brain of mice would reduce COX-2 induction after stroke. Analysis of the brains after MCAO confirmed that levels of COX2 were significantly decreased following the high-DHA diet compared with controls (-32.18%; P<0.05) and low n-3 PUFA diet (-27.63%; P<0.05; Figure 6D).

Discussion

The work presented here provides direct in vivo evidence of anti-inflammatory and neuroprotective action of dietary n-3 PUFA in prevention of ischemic injury. As revealed by in vivo biophotonic/bioluminescence imaging of TLR2 activation, chronic treatment with DHA markedly attenuated early microglial and innate immune responses after cerebral ischemia. Moreover, the comparison of stroke lesions 7 days after

Figure 3. DHA-enriched diet reduces size of ischemic lesion. Analysis of cresyl-violet-stained brain sections at day 2 A and day 7 B after MCAO revealed a significant decrease in the size of infarcted area in the ipsilateral hemisphere of mice subject to DHA-enriched diet compared with control and low n-3 PUFA diets. Infarct volume is expressed as percentage of control, nonstroked area in the contralateral hemisphere. Values indicate mean±SEM (*P<0.05). MCAO indicates middle cerebral artery occlusion; DHA, docosahexaenoic acid; SEM, standard error of the mean.

Figure 4. Dietary intake of DHA increases the levels of Bcl-2 after stroke. A, Western blot analysis showed no difference in the level of the proapoptotic protein Bax in the ischemic brains of the mice fed with the different diet. B, Significant increase in level of antiapoptotic protein Bcl-2 was detected in the brains of mice exposed to long-term DHA-enriched diet as compared with control or low n-3 PUFA diet 48 hours after cerebral ischemia (P<0.05). DHA indicates docosahexaenoic acid.
MCAO revealed a strong neuroprotective effect of the DHA-enriched diet. Interestingly, the decrease in size of ischemic lesion was accompanied by an increase in levels of the antiapoptotic molecule Bcl-2, a decrease in levels of both COX2 and the proinflammatory cytokine IL1. Importantly, long-term dietary DHA intake was associated with smaller ischemic lesions and significant increase in levels of the antiapoptotic protein Bcl2. Observed neuroprotection is consistent with previous work on rodent models of cerebral ischemia, where DHA or fish oil preparation administered days before global cerebral ischemia improved functional recovery and reduced brain injury. Moreover, recent work by Belayev et al demonstrated that DHA infused intravenously after the induction of cerebral ischemia exerts a robust neuroprotection. In addition to DHA, some novel docosanoids have been shown to inhibit poststroke infiltrated neutrophils and exert anti-inflammatory effects. Finally, DHA treatment has been shown to exert neuroprotective action in other central nervous system diseases where a strong neuroinflammatory component has been described, including Alzheimer’s and Parkinson’s diseases.

However, 1 of the most striking observations reported here is the specificity of the DHA-mediated effects. Namely, DHA-enriched diet exerted significant anti-inflammatory and neuroprotective effect, whereas α-linoleic acid from the control diet did not. This is despite the fact that dietary α-linoleic acid was partly converted into brain DHA. A likely explanation is that only DHA supplementation was effective at significantly reducing the concentration of ARA in the brain, as shown in Figure 5. The ensuing increase in DHA:ARA ratio would favor DHA competing with ARA for metabolism on membrane release, resulting in a reduction of proinflammatory derivatives such as COX-produced prostaglandins. The DHA-induced reduction of COX-2 reported here and by others would thus potentiate the reduction of proinflammatory metabolites.

Our study also provides key in vivo information on how DHA may modulate innate immune response and neuroinflammation. As shown previously, postischemic cell damage results in massive phospholipase-mediated release of free fatty acids, including ARA and DHA from the membrane phospholipids. Among those agents, DHA derivatives like neuroprotectin 1 and resolvins have been attributed anti-inflammatory properties. Here, we found that animals treated with DHA had lower brain levels of IL-1β and COX-2, increased Bcl-2, and yet TNF-α or IL-6 remained unchanged. Overall, our findings suggest that DHA had profound and specific effects against the neuroinflammatory and apoptotic ischemic cascade.

Conclusions

The results of our study clearly demonstrated that chronic DHA intake blunted inflammatory response induced by cerebral ischemia, thus preventing brain injury in an animal model. This further suggests that chronic dietary exposure of...
DHA shifts upward the n-3:n-6 PUFA ratio, thereby generating an anti-inflammatory and neuroprotective environment. Our data bring into consideration the possibility that increased DHA consumption may represent an affordable prophylactic intervention to decrease detrimental consequences of ischemic stroke.

Sources of Funding
This work was supported by the Canadian Institutes of Health Research (CIHR). J.K. is recipient of the Career Award from the R&Dand CIHR. F.C. is recipient of Fonds de la recherche en santé Québec (FRSQ) Junior-2 Award. M.L.-H. and P.C. received CIHR. F.C. is recipient of CIHR. J.K. is recipient of the Career Award from the Canadian Institutes of Health Research (CIHR). I.B. visit was sponsored by Unity for Québec (FRSQ) Junior-2 Award. M.L.-H. and P.C. received CIHR.

Disclosures
None.

References
Accumulation of Dietary Docosahexaenoic Acid in the Brain Attenuates Acute Immune Response and Development of Postischemic Neuronal Damage
Mélanie Lalancette-Hébert, Carl Julien, Pierre Cordeau, Ivan Bohacek, Yuan-Cheng Weng, Frédéric Calon and Jasna Kriz

Stroke. 2011;42:2903-2909; originally published online August 18, 2011;
doi: 10.1161/STROKEAHA.111.620856

Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2011 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/42/10/2903

Data Supplement (unedited) at:
http://stroke.ahajournals.org/content/suppl/2011/08/18/STROKEAHA.111.620856.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/
ONLINE SUPPLEMENT

SUPPLEMENTAL TABLE 1

TABLE S1. Dietary formulae and fatty acid content determined by gas chromatography
**TABLE S1. Dietary formulae and fatty acid content determined by gas chromatography**

<table>
<thead>
<tr>
<th></th>
<th>Diet A</th>
<th>Diet B Low n-3 PUFA</th>
<th>Diet C High DHA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Proteins (% w/w)</strong></td>
<td>20.3</td>
<td>20.3</td>
<td>20.3</td>
</tr>
<tr>
<td><strong>Carbohydrates (% w/w)</strong></td>
<td>65</td>
<td>65</td>
<td>65</td>
</tr>
<tr>
<td><strong>Fats (% w/w)</strong></td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td><strong>Calories per diet weight (kcal/g)</strong></td>
<td>3.9</td>
<td>3.9</td>
<td>3.9</td>
</tr>
</tbody>
</table>

**Ingredients (g/kg)**

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Diet A</th>
<th>Diet B</th>
<th>Diet C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Casein</td>
<td>200</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>dl-Methionine</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Corn starch</td>
<td>150</td>
<td>150</td>
<td>150</td>
</tr>
<tr>
<td>Sucrose</td>
<td>500</td>
<td>500</td>
<td>500</td>
</tr>
<tr>
<td>Cellulose, BW200</td>
<td>50</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>Corn oil</td>
<td>0</td>
<td>25</td>
<td>18</td>
</tr>
<tr>
<td>Safflower</td>
<td>0</td>
<td>25</td>
<td>18</td>
</tr>
<tr>
<td>MEG-3 powder (14% DHA)</td>
<td>0</td>
<td>0</td>
<td>45</td>
</tr>
<tr>
<td>Canola oil</td>
<td>40</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Soybean oil</td>
<td>10</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Choline bitartrate</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Cholesterol, USP</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
</tr>
</tbody>
</table>

**Fatty acids (g/kg)**

<table>
<thead>
<tr>
<th>Fatty Acid</th>
<th>Diet A</th>
<th>Diet B</th>
<th>Diet C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total n-3 PUFA</td>
<td>3.37</td>
<td>0.34</td>
<td>7.05</td>
</tr>
<tr>
<td>α-linolenic acid (LNA)</td>
<td>3.37</td>
<td>0.34</td>
<td>0.22</td>
</tr>
<tr>
<td>Eicosapentaenoic acid (EPA)</td>
<td>0.00</td>
<td>0.00</td>
<td>1.25</td>
</tr>
<tr>
<td>Docosahexaenoic acid (DHA)</td>
<td>0.00</td>
<td>0.00</td>
<td>5.08</td>
</tr>
<tr>
<td>Total n-6 PUFA</td>
<td>13.45</td>
<td>32.38</td>
<td>15.29</td>
</tr>
<tr>
<td>Linoleic acid (LA)</td>
<td>13.45</td>
<td>32.38</td>
<td>14.21</td>
</tr>
<tr>
<td>Arachidonic acid (ARA)</td>
<td>0.00</td>
<td>0.00</td>
<td>0.36</td>
</tr>
<tr>
<td>n-6 PUFA:n-3 PUFA ratio</td>
<td>~4.0</td>
<td>~95.0</td>
<td>~2.2</td>
</tr>
</tbody>
</table>

* Determined by gas chromatography.

Abbreviations: DHA, docosahexaenoic acid; MEG-3, High-DHA microencapsulated powder; PUFA, polyunsaturated fatty acids; USP, United States Pharmacopeia.

Notes: The formulas of these isocaloric purified diets were precisely determined to avoid batch-to-batch disparity or the presence of phytoestrogens or other common contaminants. They were the same in terms of total calories (~5 kcal/g), fibers, vitamins, minerals, and antioxidants. The control diet contained canola and soybean oil, thus providing alpha-linolenic acid, a 18 carbon n-3 PUFA. The low n-3 PUFA diet was based on safflower oil. Finally, the high DHA diet contained ~5 g of DHA and ~1.2 g of eicosapentaenoic acid (EPA, 20:5n-3) per kg of pelleted diet equivalent to a daily dose of approximately 0.7 g kg⁻¹ day⁻¹ of long-chain n-3 PUFA (assuming a mouse of 25 g eats 3 g of food per day).